Search Results
Your search for The matches 34697 pages
Showing 15801 - 15850Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
In an interim analysis of a phase II study reported in The Lancet Oncology, Makker et al found that lenvatinib plus pembrolizumab was active in advanced endometrial cancer. Study Details In the study, 54 patients from 11 sites with metastatic endometrial cancer unselected for microsatellite...
AUGMENT: Addition of Lenalidomide to Rituximab in Relapsed or Refractory Indolent Lymphoma
In the phase III AUGMENT trial reported in the Journal of Clinical Oncology, Leonard et al found that the addition of lenalidomide to rituximab significantly prolonged progression-free survival in patients with relapsed or refractory indolent lymphoma. Study Details The double-blind trial...
Differences in Medical Cannabis Use in Patients With and Without Cancer
People with and without cancer are more likely, over time, to use a more potent form of medical marijuana with increasingly higher amounts of tetrahydrocannabinol (THC), a new study published by Kim et al in the Journal of Palliative Medicine has shown. “Although there is growing...
Serum MicroRNA-371a-3p as a Biomarker for Testicular Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Dieckmann et al found that serum levels of microRNA (miR)-371a-3p (M371 test) showed very high accuracy for detecting testicular germ cell tumors. Study Details In the prospective international study, serum samples from 616 patients with...
Long-Term Outcomes for Prophylactic Cranial Irradiation vs Observation in Locally Advanced NSCLC
As reported in JAMA Oncology by Sun et al, a long-term update of the phase III NRG Oncology/RTOG 0214 trial has shown that prophylactic cranial irradiation was associated with a reduced incidence of brain metastases and improved disease-free survival—but not overall survival—compared...
AACR 2019: Does Primary Tumor Surgery Increase Survival in Patients With Advanced HER2-Positive Breast Cancer?
Surgery was associated with higher survival rates for patients with HER2-positive stage IV breast cancer compared with those who did not undergo surgery, according to results presented by Mudgway et al at the American Association for Cancer Research (AACR) Annual Meeting (Abstract 4873). Between...
AACR 2019: Maintenance Rucaparib Treatment in BRCA- or PALB2-Mutated Pancreatic Cancer
Maintenance treatment with the PARP inhibitor rucaparib was well tolerated and showed activity among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim analysis of an ongoing phase II clinical...
AACR 2019: Effect of Timing of Radiotherapy on Mucositis in Patients With Head and Neck Cancer
New research presented by Gu et al at the American Association for Cancer Research (AACR) Annual Meeting 2019 found that administering radiation treatments in the morning as opposed to later in the day may significantly reduce the severity of mucositis and its related impacts (Abstract 4860). ...
Racial Disparities in Matched Volunteer Stem Cell Donors
Although the pool of registered bone marrow donors has increased in recent years, a new study suggests that most patients of southern European and non-European descent are unlikely to have a suitable match if they need a bone marrow transplant. If an immediate registry search does not identify a...
Geriatric Assessment, Hospitalization, and Long-Term Care Use in Older Cancer Survivors
In a study reported in the Journal of Oncology Practice, Williams et al found that items in geriatric assessment were significantly predictive of hospitalization frequency and long-term care use among older cancer survivors. Study Details The study included 125 patients aged ≥ 65 years from...
BEACON Colorectal Cancer Trial: Safety Lead-in With Triplet Therapy for BRAF V600E–Mutant Metastatic Disease
As reported in the Journal of Clinical Oncology by Van Cutsem et al, treatment with encorafenib, binimetinib, and cetuximab for BRAF V600E–mutant metastatic colorectal cancer was associated with a manageable safety profile and evidence of activity in the safety lead-in to the phase III BEACON ...
AACR 2019: Entinostat Plus Pembrolizumab in Patients With Melanoma Previously Treated With Anti–PD-1 Therapy
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab showed clinical responses in patients with melanoma that had progressed on prior anti–PD-1 treatment, according to results from the phase...
AACR 2019: Higher BMI Before Age 50 May Increase Risk of Pancreatic Cancer
A higher body mass index (BMI) before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess weight at older age, according to the results of a study presented by Jacobs et al at the American Association for Cancer Research (AACR) Annual Meeting 2019 (Abstract...
AACR 2019: Gilteritinib in Patients With FLT3-Mutated Acute Myeloid Leukemia
Treatment with the FLT3-targeted therapeutic gilteritinib improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring an FLT3 mutation compared with standard chemotherapy regimens, according to results from the phase III ADMIRAL trial presented by Perl et al at ...
Germline Mutations and Risk for Neoplastic Disease Progression During Pancreatic Surveillance
In a study reported in the Journal of Clinical Oncology, Abe et al found previously unidentified deleterious germline mutations in patients with family history as the basis for pancreatic surveillance. Moreover, the study showed the risk of pancreatic cancer was higher in individuals with germline...
AACR 2019: CD40 Antibody Combined With Chemotherapy in Advanced Pancreatic Cancer
An interim analysis of a small phase Ib study by O’Hara et al evaluating the CD40 agonistic monoclonal antibody APX005M in combination with gemcitabine and nab-paclitaxel with or without the programmed cell death protein 1 (PD-1) inhibitor nivolumab in untreated patients with metastatic...
AACR 2019: Data Analysis Shows Activity of Pembrolizumab in Pretreated Patients With Advanced Small Cell Lung Cancer
The results of an analysis of pooled data from the phase Ib KEYNOTE-028 trial and the phase II KEYNOTE-158 study of the anti–programmed cell death protein 1 monoclonal antibody pembrolizumab in the treatment of advanced small cell lung cancer has found that the therapy provided antitumor...
AACR 2019: HER2-Targeted CAR T-Cell Therapy Plus Chemotherapy in Advanced Sarcoma
A small phase I study by Navai et al investigated a combination of lymphodepletion chemotherapy and HER2-specific chimeric antigen receptor (CAR) T-cell therapy for pediatric and adult patients with advanced HER2-positive sarcoma. The combination showed promising antitumor activity and was found to ...
FDA Oncology Center of Excellence Issues Annual Report
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has issued its 2018 Annual Report, including updates on regulatory reviews and initiatives, OCE programs, guidances, and more. Regulatory Reviews The OCE is tasked with clinical medical oncology reviews, irrespective...
FDA Pipeline: Mammography Policies, Designations for Leukemias and Myelodysplastic Syndrome
This week, the U.S. Food and Drug Administration (FDA) announced policy changes to modernize mammography policies and issued a Breakthrough Therapy designation, an Orphan Drug designation, and an investigational new drug application. FDA Advances Policy Changes to Modernize Mammography Services...
Risk of Subsequent Primary Cancers After Carbon Ion Radiotherapy for Localized Prostate Cancer
In a Japanese retrospective study reported in The Lancet Oncology, Mohamad et al found that carbon ion radiotherapy was associated with a lower risk of subsequent primary cancers compared with photon radiotherapy in patients with localized prostate cancer. The study included data on 1,455 patients ...
Venetoclax Plus Low-Dose Cytarabine in Older Patients With Previously Untreated AML Ineligible for Intensive Chemotherapy
In a phase Ib/II trial reported in the Journal of Clinical Oncology, Wei et al found that the combination of venetoclax and low-dose cytarabine produced a high response rate in previously untreated older patients with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy. In...
Characteristics and Prognosis Associated With Thin Nodular Primary Melanomas
In a study reported in the Journal of the National Cancer Institute, Dessinioti et al found that thin nodular primary melanomas are associated with aggressive characteristics that may portend poorer prognosis vs superficial spreading melanomas. Study Details The study involved data on 5,062...
Lorlatinib in Advanced NSCLC With ALK Resistance Mutations
In a study reported in the Journal of Clinical Oncology, Shaw et al found that lorlatinib showed greater efficacy in patients with vs without anaplastic lymphoma kinase (ALK) resistance mutations among patients with advanced ALK-positive non–small cell lung cancer (NSCLC) in whom one or more...
Antoni Ribas, MD, PhD, Elected AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Antoni Ribas, MD, PhD, as their President-Elect for 2019–2020. He will officially become President-Elect at the AACR Annual Meeting 2019 and he will assume the presidency in April 2020 at the AACR Annual Meeting...
Keratinocyte Carcinoma: Update on Treatment and Prevention
Keratinocyte carcinoma, previously known as nonmelanoma skin cancer, is the most common malignancy in fair-skinned populations worldwide. In a review article published in Current Opinion in Pharmacology, Alexander Zink, MD, MPH, PhD, of the Technical University of Munich, proposed that...
Looking for Trusted Patient Information Resources?
CHECK OUT ASCO Answers patient education materials in the ASCO University Bookstore. ASCO Answers includes award-winning guides, fact sheets, and booklets covering a broad range of important and popular topics in cancer care. Bulk quantities of these high-quality print materials are available at...
ASCO Weighs in on Widespread Youth Tobacco Use: See the Latest National Youth Tobacco Survey Results
APPROXIMATELY 5 MILLION middle and high school students reported currently using a tobacco product, with over 3.6 million currently using e-cigarettes and about 2.5 million currently using a combustible tobacco product, according to the latest findings from the National Youth Tobacco Survey ...
Urge Congress to Support Medicaid Coverage of Routine Care Costs for Clinical Trials
MEMBERS OF CONGRESS recently reintroduced bipartisan legislation, the ‘Covering Life-Saving Investigations Needed in Cancer and Other Life-Threatening Conditions Through Timely Use of Resources for Easy and Affordable Treatment from Medicaid for Enrollees in Need Today Act,’ or the CLINICAL...
Conquer Cancer Honors Researchers With Merit Awards
ASCO’S CONQUER CANCER FOUNDATION is pleased to announce the recipients of the Gastrointestinal Cancers, Genitourinary Cancers, and Clinical Immuno-Oncology Symposium Merit Awards. Conquer Cancer Merit Awards recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to...
ASCO Multidisciplinary Cancer Management Course in Azerbaijan: A Well-Attended Success
The National Center of Oncology (NCO) in Azerbaijan partnered with ASCO, the American Society for Clinical Pathology (ASCP), and the Oncology Nursing Society (ONS) to conduct a highly successful Multidisciplinary Cancer Management Course (MCMC) in September 2018 in Baku, Azerbaijan. The conference...
New ASCO Guideline Makes Safe Handling of Hazardous Drugs a Priority
ASCO HAS PUBLISHED a new guideline, “Safe Handling of Hazardous Drugs: ASCO Standards,” to promote the safety of pharmacists, nurses, and all staff who handle potentially dangerous medicines, such as chemotherapy compounds.1 Safety is pivotal in the entire drug workflow, including drug mixing and...
ASCO Endorses Active Surveillance Guideline for Low-Risk Prostate Cancer
ASCO ENDORSES and reinforces the evidence-based American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) Guideline published in 2018 in the Journal of Urology. ASCO’s endorsement of a guideline on clinically localized...
CancerCare Celebrates 75 Years of Serving the Cancer Community
RECENTLY, CANCERCARE celebrated its 75th anniversary by revealing a new campaign, “If It Matters To You, It Matters To Us.” The campaign highlights CancerCare’s commitment to holistic, patient-centered support services and comprehensive care for people living with cancer. The new messaging features ...
Prostatectomy vs Watchful Waiting: Clinical Dilemma Centers on Aggressive vs Indolent Disease
THE MANAGEMENT of localized prostate cancer remains controversial. Although the widespread use of prostate-specific antigen (PSA) testing has resulted in a dramatic increase in the diagnosis and treatment of prostate cancer, many men do not benefit from intervention because the disease is either...
National Cancer Institute Designates Comprehensive Cancer Center Status to NYU Langone’s Perlmutter Cancer Center
NYU LANGONE Health’s Laura and Isaac Perlmutter Cancer Center has been designated a Comprehensive Cancer Center by the National Cancer Institute (NCI). Perlmutter Cancer Center is now among 50 cancer centers across the country to earn this distinction. Perlmutter Cancer Center received an overall...
Radical Prostatectomy or Watchful Waiting: 29-Year Follow-up of Scandinavian Trial
AS REPORTED in The New England Journal of Medicine by Anna Bill-Axelson, MD, PhD, Lars Holmberg, MD, PhD, both of Uppsala University Hospital, and and colleagues, the 29-year follow-up of the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) trial has shown that radical prostatectomy is...
Expert Point of View: Kenneth Shain, MD, PhD
KENNETH SHAIN, MD, PhD, Director of the Myeloma Working Group at Moffitt Cancer Center, Tampa, Florida, told The ASCO Post that ixazomib is “an effective drug,” but he is not ready to use it as maintenance therapy. He noted that the TOURMALINE-MM3 trial did meet its primary endpoint—but not...
Maintenance Ixazomib Delays Disease Progression in Newly Diagnosed Myeloma
IN PATIENTS with newly diagnosed multiple myeloma who responded well to induction therapy and underwent transplant, 2 years of maintenance therapy with ixazomib led to a 38% improvement in progression-free survival compared with placebo, according to the results of the phase III TOURMALINE-MM3...
Expert Point of View: Ajay K. Nooka, MD, MPH
THE ASCO POST asked Ajay K. Nooka, MD, MPH, Associate Professor, Division of Bone Marrow Transplant at Winship Cancer Institute, Emory University, to comment on studies involving daratumumab. “After the phase III SWOG S0777 trial demonstrated a survival benefit with a 3-drug induction regimen...
ASH Reports Show Benefit of Adding Daratumumab to Initial Therapy in Multiple Myeloma
DARATUMUMAB APPEARS to be the “gift that keeps on giving” to the myeloma community. “It seems we can add daratumumab to almost anything and make the regimen better. It’s got good activity and a good safety profile,” said Kenneth Shain, MD, PhD, Director of the Myeloma Working Group at Moffitt...
Expert Point of View: Matthew P. Goetz, MD
“WHAT’S IMPORTANT for clinicians to take away from this analysis is that there is clearly zero benefit of atezolizumab/nab-paclitaxel in patients with programmed cell death ligand 1 (PD-L1)-negative disease. In PD-L1–positive patients, the combination improves progression-free survival and overall ...
IMpassion130 Substudy: Atezolizumab/Nab-Paclitaxel Survival Benefits Limited to PD-L1–Positive Triple-Negative Breast Cancer
THE PHASE III IMpassion130 trial, first reported at the European Society for Medical Oncology (ESMO) 2018 Congress1 and published in The New England Journal of Medicine,2 found that the combination of front-line atezolizumab plus nab-paclitaxel significantly improved disease-free and overall...
University of Florida Receives $12 Million Gift for Brain Tumor Research
THE UNIVERSITY OF FLORIDA received a $12 million gift from The Harris Rosen Foundation to advance innovative brain tumor immunotherapy research and care at the University of Florida Health and to launch an unprecedented partnership for the development of novel brain tumor treatments. The Rosen gift ...
FDA Grants Accelerated Approval to Atezolizumab/ Nab-paclitaxel in Triple-Negative Breast Cancer
ON MARCH 8, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for the treatment of adults with unresectable, locally advanced or metastatic, PD-L1–positive triple-negative breast cancer. PD-L1 status is determined by...
New ASCO Guideline on Head and Neck Cancer Clarifies Lymph Node Management
A NEW ASCO guideline, “Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline,” aims to clarify issues in lymph node management.1 “This guideline represents a true multidisciplinary synthesis of some important new information about...
FDA Commissioner Scott Gottlieb, MD, Resigns
ON MARCH 5, 2019, Scott Gottlieb, MD, announced his resignation as Commissioner of the U.S. Food and Drug Administration (FDA), a post he began in 2017. Dr. Gottlieb’s resignation will be effective in April. In a resignation letter to Alex M. Azar II, Secretary of Health and Human Services (HHS),...
NCCN Summit Tackles Inequities in Access to Care
WHEN BRANDON CANYON’S mother Leone was diagnosed with uterine cancer, he drove her to treatment sessions at the nearest cancer center—a 200-mile round trip on rough roads. Gas was a significant expense, but their only other option was to forgo treatment. The Canyons are members of the Navajo...
American Society of Breast Surgeons Recommends Genetic Testing for Newly Diagnosed Patients With Breast Cancer
IN A MOVE that is a significant departure from current testing recommendations, the American Society of Breast Surgeons (ASBrS) recommends that genetic testing be available to all individuals newly diagnosed with breast cancer.1 The new recommendations expand on common restrictions by the National...
City of Hope Awarded Lymphoma SPORE Grant
CITY OF HOPE announced recently that it received its third lymphoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). The grant covers a 5-year period and totals $12.5 million. SPORE grants involve both basic as well as clinical and applied...
